Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
37.84
+1.63 (4.50%)
At close: Aug 6, 2025, 4:00 PM
37.72
-0.12 (-0.32%)
After-hours: Aug 6, 2025, 4:29 PM EDT
Verve Therapeutics Analyst Ratings
Total Analysts
6
Consensus Rating
Buy
Price Target
$57.40
Upside
+51.69%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $71 → $65 | Buy | Maintains | $71 → $65 | +71.78% | Jul 28, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $52 → $51 | Strong Buy | Maintains | $52 → $51 | +34.78% | Jul 22, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $74 → $71 | Buy | Maintains | $74 → $71 | +87.63% | May 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $58 | Strong Buy | Reiterates | $58 | +53.28% | Feb 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 18, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $55 → $57 | Buy | Maintains | $55 → $57 | +50.63% | Dec 10, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $53 → $75 | Buy | Maintains | $53 → $75 | +98.20% | Dec 9, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $55 | Buy | Reiterates | $55 | +45.35% | Nov 1, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $51 → $53 | Buy | Maintains | $51 → $53 | +40.06% | Nov 1, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $51 | Buy | Initiates | $51 | +34.78% | Oct 16, 2024 |
| Raymond James | Raymond James | Buy Initiates $51 | Buy | Initiates | $51 | +34.78% | Oct 10, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $60 → $56 | Buy → Hold | Downgrades | $60 → $56 | +47.99% | Sep 27, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 20, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $55 | Buy | Reiterates | $55 | +45.35% | Sep 19, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $53 → $55 | Buy | Maintains | $53 → $55 | +45.35% | Aug 2, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 17, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.